mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|14|13|1381-1387

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.14, Iss.13, 2007-06, pp. : 1381-1387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitors in the treatment of cancer

By Fasolo Angelica   Sessa Cristiana  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1717-1734

Informa Healthcare

Access to resources Recommend Favorite

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite

Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents

By  

Current Cancer Drug Targets, Vol. 4, Iss. 8, 2004-12 ,pp. : 621-635

Bentham Science Publishers

Access to resources Recommend Favorite

Use of mTOR inhibitors in the treatment of malignancies

By Mohindra Nisha A   Giles Francis J   Platanias Leonidas C  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 979-990

Informa Healthcare

Access to resources Recommend Favorite

The promise of mTOR inhibitors in the treatment of colorectal cancer

By Kim Dae-Dong   Eng Cathy  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1775-1788

Informa Healthcare

Access to resources Recommend Favorite